In laboratories at the University of Oregon, scientists have reached 160 million years into the past to resurrect proteins from the earliest mammals — and some of these ancient molecules kill bacteria more effectively than the drugs we rely on today. The work centers on lactoferrin, an immune protein carried in breast milk and tears, and the antimicrobial peptide hidden within it that ruptures bacterial cell walls. By tracing the evolutionary history of this protein back to the common ancestor of all placental mammals, researchers are not merely studying the past — they are reading nature's lo
Ancient Lactoferrin Proteins Offer Blueprint for Next-Generation Antimicrobials
Some ancient peptides killed bacteria better than modern ones
Mark
So they literally reconstructed proteins from 160 million years ago? How is that even possible?
Mimi
They didn't dig up the actual proteins—those would have degraded long ago. Instead, they compared lactoferrin sequences from modern animals like humans and cows, then used computational methods to infer what the ancestral versions must have looked like. It's like reconstructing an ancestor's face from family resemblances across generations.
Luke
Right, but that's an inference, not a fossil. The actual ancient sequence is a prediction based on a model. How confident are they in that prediction?
Mimi
They used AlphaFold2 to model the structures, which is pretty reliable for protein folding. And then they actually synthesized the peptides and tested them in the lab against real bacteria. So the predictions were testable.
Mark
And some of the ancient versions actually worked better than modern ones?
Mimi
Yes. They tested against four major pathogens and found that certain ancestral lactoferricins had higher antimicrobial activity than the versions we see in living animals today. That was surprising—you'd expect evolution to keep improving.
Luke
But "higher activity" in a lab test—does that tell us anything about what would happen in an actual infection, or in a human body?
Mimi
That's the gap. These are in vitro tests, peptide against bacteria in controlled conditions. Getting from there to a drug that works in patients is a much longer road.
Mark
What's the actual mechanism? How do these peptides kill bacteria?
Mimi
They punch holes in bacterial cell membranes. The team identified that specific amino acid changes—particularly one arginine substitution—made the ancient versions better at doing that.
Luke
And Barber acknowledged that bacteria will eventually resist these peptides too, right?
Mimi
Exactly. He said the real value isn't finding a permanent solution, but understanding how resistance evolves so we can design combination treatments or better targeting strategies.
Mark
So this is more about learning from evolution than about having a cure ready to go.
Mimi
That's it. It's a proof of concept that ancient biology can teach us something useful about drug design.
The Pulse
- Antibiotic resistance is accelerating faster than new drugs can be developed, leaving medicine in urgent need of entirely new blueprints for killing bacteria.
- University of Oregon scientists resurrected 160-million-year-old proteins using genetic reconstruction and AI-assisted structure prediction, then tested them against four serious human pathogens in the lab.
- Some ancient versions of the antimicrobial peptide lactoferricin outperformed their modern counterparts — revealing that evolution did not march in a straight line toward greater potency, and that older forms were sometimes deadlier.
- A single amino acid substitution — one arginine swap — proved pivotal to the peptide's bacteria-killing power, offering a precise molecular target for drug designers.
- Researchers caution that bacteria will eventually resist these ancient peptides too, but understanding the evolutionary patterns of that resistance could enable smarter combination therapies.
- The work is years from producing actual drugs, yet it reframes the search for new medicines as an act of reading what nature already solved — and learning to stay one step ahead.
In laboratories at the University of Oregon, scientists have reached 160 million years into the past to resurrect proteins from the earliest mammals — and some of these ancient molecules kill bacteria more effectively than the drugs we rely on today. The work centers on lactoferrin, an immune protein carried in breast milk and tears, and the antimicrobial peptide hidden within it that ruptures bacterial cell walls. By tracing the evolutionary history of this protein back to the common ancestor of all placental mammals, researchers are not merely studying the past — they are reading nature's longest-running experiment in survival, hoping its lessons can guide medicine through the growing crisis of antibiotic resistance.
A research team at the University of Oregon has resurrected proteins from the earliest mammals — reaching back 160 million years — and discovered that some of these ancient molecules kill bacteria more effectively than modern antimicrobials. The scientists focused on lactoferrin, an immune protein found in breast milk, tears, and saliva, which fights infection in two ways: by starving bacteria of iron and by deploying an embedded peptide called lactoferricin that ruptures bacterial cell walls. What puzzled the researchers was that none of lactoferrin's close relatives share this bacteria-killing ability, raising the question of how and when it evolved.
To find out, the team compared lactoferrin sequences from modern humans and cows, worked backward through evolutionary time to reconstruct ancestral versions, and used the AI tool AlphaFold2 to predict their three-dimensional structures. They then synthesized the ancient peptides and tested them against four serious pathogens: Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, and Streptococcus agalactiae. The results were striking — some ancestral forms of lactoferricin outperformed the versions found in living animals today, suggesting evolution had not moved in a straight line toward greater potency.
The team traced this killing power to an accumulation of specific amino acid changes in the lactoferricin domain over millions of years, with one arginine substitution proving especially critical. Senior author Matt Barber described the project as reading nature's own long experiment: by studying which traits persisted through natural selection, researchers can extract principles for designing new antimicrobial drugs at a moment when resistance to existing antibiotics is spreading dangerously.
Barber was careful to temper the excitement. Turning these ancient proteins into actual medicines remains years away, and bacteria will eventually develop resistance to these peptides as well. But that resistance need not be the end of the story — if scientists can anticipate the evolutionary moves pathogens will make, they may be able to design combination treatments that make resistance far harder to achieve. The ancient proteins are less a final answer than a map of how life has always solved the problem of survival.
A team at the University of Oregon has done something that sounds like science fiction: they've brought ancient proteins back to life, and some of them kill bacteria better than the drugs we use today. These weren't dinosaur proteins—they came from the earliest mammals, reaching back 160 million years into the past. The researchers reconstructed them using genetic detective work, comparing the lactoferrin proteins found in modern humans and cows, then working backward through evolutionary time to infer what their ancestors looked like. Once they had the ancient sequences, they used AlphaFold2 to predict their three-dimensional structures, then synthesized the peptides in the lab and tested them against four serious human pathogens: Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, and Streptococcus agalactiae.
Lactoferrin is an immune protein that lives in breast milk, tears, and saliva—but not in blood. It works in two ways. First, it starves bacteria by binding to iron, an element pathogens need to survive. Second, it contains an embedded antimicrobial peptide called lactoferricin that punches holes in bacterial cell walls, causing them to burst. The puzzle that drew the researchers' attention was this: none of lactoferrin's close relatives have this bacteria-killing ability. Why did only this one protein evolve such a potent weapon? To answer that question, they traced the protein's history all the way back to its origin in the common ancestor of all placental mammals.
What they found was an accumulation of specific amino acids—cationic and hydrophobic residues—in the lactoferricin domain over millions of years. These chemical changes, the team believes, gave the ancient version of the peptide its ability to rupture bacterial membranes. One particular substitution, a single arginine swap, turned out to be crucial. The researchers measured how well ancestral and modern versions of lactoferricin killed bacteria by growing cultures at different concentrations and tracking growth rates. The results were striking: some of the ancient peptides showed higher antimicrobial activity than the versions we find in living animals today. Evolution, in other words, had not moved in a straight line toward greater potency. Some ancestral forms were actually more effective killers than their modern descendants.
Matt Barber, the senior author, framed the work as a way of reading nature's own long experiment. "Evolution is essentially a billions-year-old science experiment," he said. "We're seeing the results of what worked and what didn't work." By studying how traits emerge and persist through natural selection, researchers can extract principles useful for designing new antimicrobial tools. The potential is real: as antibiotic resistance spreads and bacteria develop defenses against existing drugs, ancient peptides offer a fresh blueprint for next-generation medicines.
But Barber was careful not to oversell the promise. We are still years away from turning these ancient proteins into actual drugs, he cautioned. And there is a harder truth beneath the excitement: bacteria will eventually develop resistance to these peptides too. That resistance is not inevitable doom, though. If scientists can understand how pathogens become resistant to these molecules—if they can anticipate the evolutionary moves bacteria will make—they might design better ways to target them or create combination treatments that make resistance harder to achieve. The ancient proteins are not a final answer. They are a map of how evolution solves the problem of survival, and that map might help us stay one step ahead.
Notable Quotes
Evolution is essentially a billions-year-old science experiment. We're seeing the results of what worked and what didn't work.— Matt Barber, senior author
If we understand and can anticipate how pathogens become resistant to these molecules, we can hopefully find better ways to target them or develop combination treatments that better avoid resistance.— Matt Barber
Want the full story?
Read the original at BioTechniques ↗
Health & Medicine